close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mereo BioPharma Group plc - American Depositary Shares (NQ:MREO)

0.4467 +0.0257 (+6.10%)
Streaming Delayed Price Updated: 2:19 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Mereo BioPharma Group plc - American Depositary Shares

< Previous 1 2 3 Next >
News headline image
MREO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Stockholders Who Lost Money Investing in Mereo BioPharma Group plc Should Contact Robbins LLP for Information About Recovering Their Losses from MREO
From Robbins LLP
Via GlobeNewswire
News headline image
CLASS ACTION ALERTS: Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ultragenyx and Mereo BioPharma and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines – MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
MREO SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Mereo (MREO) Investors of Securities Class Action Deadline on April 6, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MREO
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
MREO Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Mereo BioPharma Group plc Class Action
From Robbins LLP
Via GlobeNewswire
News headline image
ATTENTION NASDAQ: MREO INVESTORS: Contact Berger Montague About a Mereo BioPharma Group PLC Class Action Lawsuit
From Berger Montague
Via GlobeNewswire
News headline image
ROSEN, LEADING INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MREO
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MREO
From DJS Law Group
Via Business Wire
News headline image
MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
MEREO LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Mereo BioPharma Group plc and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Mereo BioPharma
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Rosen Law Firm Urges Mereo BioPharma Group plc (NASDAQ: MREO) Stockholders to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Mereo BioPharma Group plc Securities Class Action Lawsuit
From Robbins LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Mereo BioPharma Group plc – MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Mereo BioPharma Provides Corporate Update
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today